By Christy Santhosh (Reuters) -Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

Levi & Korsinsky is representing the shareholder plaintiff in a suit claiming the Ozempic and Wegovy manufacturer withheld ...

Novo Nordisk (NVO) files additional court cases against vendors selling cheaper semaglutide knockoffs. Read more here.

Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...

European shares closed higher on Tuesday, buoyed by better-than-expected corporate earnings and renewed optimism that the ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

Novo Nordisk is scheduled to report results for the second quarter on Wednesday. Here is what you need to know: PROFIT FORECAST: The company pre-released preliminary second-quarter numbers last week, ...

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

(Reuters) -Shares in Wegovy maker Novo Nordisk fell around 4% on Friday to their lowest since August 2021, after U.S.

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.